245 related articles for article (PubMed ID: 31345399)
41. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
Mercadante S; Prestia G; Adile C; Casuccio A
J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
[TBL] [Abstract][Full Text] [Related]
42. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
[TBL] [Abstract][Full Text] [Related]
43. Opioids for the management of breakthrough pain in cancer patients.
Zeppetella G; Davies AN
Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
[TBL] [Abstract][Full Text] [Related]
44. A Longitudinal Study of Breakthrough Cancer Pain: An Extension of IOPS-MS Study.
Mercadante S; Caraceni A; Cuomo A; Mammucari M; Marchetti P; Mediati RD; Natoli S; Tonini G
J Clin Med; 2021 May; 10(11):. PubMed ID: 34073907
[TBL] [Abstract][Full Text] [Related]
45. Impact of breakthrough pain on community-dwelling cancer patients: results from the National Breakthrough Pain Study.
Katz NP; Gajria KL; Shillington AC; Stephenson JJ; Harshaw Q
Postgrad Med; 2017 Jan; 129(1):32-39. PubMed ID: 27846789
[TBL] [Abstract][Full Text] [Related]
46. The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs.
Giuliani J; Fiorica F; Sacchetto A; Franceschini G; Vaccari F; Bonetti A
J Oncol Pharm Pract; 2021 Mar; 27(2):445-447. PubMed ID: 33356990
[TBL] [Abstract][Full Text] [Related]
47. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study.
Hashemi M; Zali A; Golmakani E; Delshad MH; Shadnoush M; Akbari ME
Daru; 2021 Jun; 29(1):51-59. PubMed ID: 33475984
[TBL] [Abstract][Full Text] [Related]
48. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain.
Portenoy RK; Burton AW; Gabrail N; Taylor D;
Pain; 2010 Dec; 151(3):617-624. PubMed ID: 20800358
[TBL] [Abstract][Full Text] [Related]
49. Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care.
Chang A; Roeland EJ; Atayee RS; Revta C; Ma JD
J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):247-60. PubMed ID: 26368648
[TBL] [Abstract][Full Text] [Related]
50. The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Maltoni M; Russo D; Adile C; Ferrera P; Rossi R; Rosati M; Casuccio A
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33801478
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
Jandhyala R; Fullarton JR; Bennett MI
J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
[TBL] [Abstract][Full Text] [Related]
52. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group.
Mercadante S; Marchetti P; Cuomo A; Mammucari M; Caraceni A;
Support Care Cancer; 2016 Feb; 24(2):961-968. PubMed ID: 26438145
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
[TBL] [Abstract][Full Text] [Related]
54. [Transmucosal fentanyl administration: sublingual, buccal, nasal - all the same? Treatment of breakthrough cancer pain].
Überall MA
MMW Fortschr Med; 2017 Oct; 159(Suppl 6):15-22. PubMed ID: 29557092
[TBL] [Abstract][Full Text] [Related]
55. Fentanyl for breakthrough cancer pain: where are we?
Meriggi F; Zaniboni A
Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
[TBL] [Abstract][Full Text] [Related]
56. Fentanyl pectin nasal spray for painful mucositis in head and neck cancers during intensity-modulated radiation therapy with or without chemotherapy.
Mazzola R; Ricchetti F; Fiorentino A; Giaj-Levra N; Fersino S; Tebano U; Albanese S; Gori S; Alongi F
Clin Transl Oncol; 2017 May; 19(5):593-598. PubMed ID: 27853984
[TBL] [Abstract][Full Text] [Related]
57. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain.
Davies A; Kleeberg UR; Jarosz J; Mercadante S; Poulain P; O'Brien T; Schneid H; Kress HG
Support Care Cancer; 2015 Jul; 23(7):2135-43. PubMed ID: 25556611
[TBL] [Abstract][Full Text] [Related]
58. Fentanyl pectin nasal spray for breakthrough cancer pain.
Taylor DR; Gabrail N
Future Oncol; 2012 Feb; 8(2):121-30. PubMed ID: 22335576
[TBL] [Abstract][Full Text] [Related]
59. A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting.
Baek SK; Kim DY; Kang SY; Sym SJ; Kim YS; Lee JY
Cancer Res Treat; 2016 Apr; 48(2):768-74. PubMed ID: 26511815
[TBL] [Abstract][Full Text] [Related]
60. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes.
Zeppetella G; Davies A; Eijgelshoven I; Jansen JP
J Pain Symptom Manage; 2014 Apr; 47(4):772-785.e5. PubMed ID: 23981487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
